C
Cybin Inc
F:R7E1
Cybin Inc
F:R7E1
Price:
13
EUR
17.12%
Market Cap:
€9.9B
Relative Value
There is not enough data to reliably calculate the relative value of R7E1.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
R7E1
Relative Value
Base Case
Not Available
C
Multiples Across Competitors
R7E1 Competitors Multiples
Cybin Inc Competitors
Cybin Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CA |
C
|
Cybin Inc
F:R7E1
|
6B EUR | 0 | -62.4 | -62.7 | -62.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
952.4B USD | 14.6 | 46.1 | 31.1 | 33.2 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
592.2B USD | 6.3 | 22.1 | 15.3 | 18.8 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
284.1B CHF | 4.6 | 30.2 | 12.8 | 14.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
243.9B CHF | 5.6 | 22.4 | 13.8 | 17.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
234.8B GBP | 5.3 | 30.7 | 17 | 23.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
298.8B USD | 4.6 | 16.4 | 10.1 | 12.4 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.6 | 10.8 | 8 | 9.3 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.6B USD | 2.4 | 19.5 | 7.5 | 10 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
125.8B USD | 2.6 | 17.8 | 7.4 | 9.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
